Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Tulsa, OK
NPI: 1356382592Primary Practice Location
Oklahoma Cancer Specialists and Research Institute LLC
12697 E 51st S St, Tulsa, OK
Primary Employer
Oklahoma Cancer Specialists and Research Institute LLC
ocsri.org
HQ Phone
Get M.D. Mark's Phone Numberphone_androidMobile
Get M.D. Mark's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOK State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 419 | 1,259 |
| 2 | 80053Blood test, comprehensive group of blood chemicals | 386 | 1,216 |
| 3 | 36415Insertion of needle into vein for collection of blood sample | 383 | 1,008 |
| 4 | 83735Magnesium level | 379 | 1,209 |
| 5 | 84100Phosphate level | 379 | 1,209 |
Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Authors: Myo Min, Joseph Mace, Romeo Mandanas, Philip Bonomi
Publication Date: 2013-02-02
Authors: Craig Reynolds, Philip Bonomi, Mark Socinski, Edward Garon, David Spigel
Publication Date: 2014-11-18
Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Authors: Philip Bonomi, Mark Socinski, Edward Garon, David Spigel
Publication Date: 2015-01-23
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Docetaxel, DRUG: Gemcitabine, DRUG: Olaratumab
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Abemaciclib, DRUG: Prednisone, DRUG: Abiraterone acetate
